Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Werewolf Therapeutics (NASDAQ:HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer treatment, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's leadership, including CEO Daniel J. Hicklin, Ph.D. and CMO Randi Isaacs, M.D., will engage in a fireside chat on September 8, 2025, at 2:00 PM EDT. The presentation will be accessible via webcast on the company's investor relations website, with a replay available for approximately 90 days.
Werewolf Therapeutics (NASDAQ:HOWL), un'azienda biofarmaceutica che sviluppa terapie attivate in modo condizionale per il trattamento del cancro, ha annunciato la sua partecipazione al 27° H.C. Wainwright Annual Global Investment Conference.
Il management, incluso il CEO Daniel J. Hicklin, Ph.D. e la CMO Randi Isaacs, M.D., parteciperà a una fireside chat il 8 settembre 2025 alle 14:00 EDT. La presentazione sarà trasmessa via webcast sul sito per gli investitori della società, con una replica disponibile per circa 90 giorni.
Werewolf Therapeutics (NASDAQ:HOWL), una compañía biofarmacéutica enfocada en desarrollar terapias activadas de forma condicional para el tratamiento del cáncer, ha anunciado su participación en la 27.ª Conferencia Anual Global de Inversión de H.C. Wainwright.
La dirección de la empresa, incluidos el CEO Daniel J. Hicklin, Ph.D. y la CMO Randi Isaacs, M.D., participará en una charla informal (fireside chat) el 8 de septiembre de 2025 a las 2:00 PM EDT. La presentación se podrá seguir por webcast en la web de relaciones con inversores de la compañía y la réplica estará disponible durante aproximadamente 90 días.
Werewolf Therapeutics (NASDAQ:HOWL)는 암 치료를 위한 조건부 활성화 치료제를 개발하는 바이오제약사로, 다가오는 H.C. Wainwright 제27회 연례 글로벌 투자 콘퍼런스에 참여한다고 발표했습니다.
회사의 경영진인 CEO Daniel J. Hicklin, Ph.D. 및 CMO Randi Isaacs, M.D.는 2025년 9월 8일 EDT 기준 오후 2시에 파이어사이드 채팅(fireside chat)에 참석합니다. 발표는 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있으며, 약 90일간 재시청이 가능합니다.
Werewolf Therapeutics (NASDAQ:HOWL), une société biopharmaceutique spécialisée dans le développement de médicaments activés de manière conditionnelle pour le traitement du cancer, a annoncé sa participation à la 27e conférence annuelle mondiale d'investissement H.C. Wainwright.
La direction de l'entreprise, notamment le CEO Daniel J. Hicklin, Ph.D. et la CMO Randi Isaacs, M.D., participera à une discussion informelle (fireside chat) le 8 septembre 2025 à 14h00 EDT. La présentation sera diffusée en webcast sur le site relations investisseurs de la société, avec une rediffusion disponible pendant environ 90 jours.
Werewolf Therapeutics (NASDAQ:HOWL), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung bedingt aktivierbarer Therapeutika zur Krebsbehandlung spezialisiert hat, hat seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference angekündigt.
Die Unternehmensführung, darunter CEO Daniel J. Hicklin, Ph.D. und CMO Randi Isaacs, M.D., wird am 8. September 2025 um 14:00 Uhr EDT an einem Fireside-Chat teilnehmen. Die Präsentation wird per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein; ein Replay wird für etwa 90 Tage abrufbar sein.
- None.
- None.
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 2:00 PM EDT on Monday, September 8, 2025, at the H.C. Wainwright 27th Annual Global Investment Conference, taking place on September 8-10, 2025.
A live webcast link for the presentation will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated INDUKINE™ and INDUCER™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple solid tumor types as a single agent. Werewolf is leveraging positive data from its INDUKINE molecules to advance the development of INDUCER molecules. Werewolf’s first INDUCER development candidate, WTX-1011, targets STEAP1 for prostate cancer. To learn more visit www.werewolftx.com.
Investor Contact:
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the H.C. Wainwright Conference?
Who will be presenting for Werewolf Therapeutics at the H.C. Wainwright Conference?
How can investors access Werewolf Therapeutics' H.C. Wainwright Conference presentation?
What does Werewolf Therapeutics (HOWL) specialize in?
